Drug intelligence / Profile preview

STAR0603

Development stage: Preclinical
Lead developer: Marengo Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

STAR0603 is a preclinical-stage, wholly-owned bispecific precision T-cell agonist being developed by Marengo Therapeutics for the treatment of oncology. Generated from Marengo's proprietary Selective T Cell Activation Repertoire (STAR) platform, STAR0603 is designed to selectively activate and expand specific T-cell subsets to promote durable anti-tumor immune responses while minimizing systemic toxicity.

Other names: STAR 0603STAR0603STAR-0603

Targets

TRBV10 (T-cell receptor beta variable 10)TRBV6 (T-cell receptor beta variable 6)CD2 (T-cell Surface Antigen CD2)

Beyond the preview

Go deeper on STAR0603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STAR0603.

Explore the full profile